Grifols breaks ground on new manufacturing site in Spain

Barcelona, June 3, 2026 – Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), a global healthcare company and leader in the production of plasma-derived medicines, today held the groundbreaking ceremony for its new plant in Lliçà de Vall (Barcelona). The facility, expected to begin operations in 2030, will strengthen the company's industrial capacity in Catalonia to meet the growing demand for plasma-derived medicines in Europe.

The event was attended by the President of the Government of Spain, Pedro Sánchez; the Minister of Industry and Trade of the Spanish government, Jordi Hereu; the Minister for Research and Universities of the Government of Catalonia, Núria Montserrat; the Secretary of State and Director of the Office for Economic Affairs and the G20, Manuel de la Rocha; the Mayor of Lliçà de Vall, Xavier Castillejo; among other authorities, as well as the Vice Chairman of the Grifols Board of Directors, Raimon Grifols, and Board members Víctor Grifols Deu, Albert Grifols Coma-Cros and Tomás Dagá.

In his remarks, Pedro Sánchez highlighted that “this new facility represents a major step forward for Grifols and will help strengthen Europe’s strategic autonomy in the healthcare, industrial, and technology sectors.” He added, “We will continue to support the pharmaceutical and biotechnology industries, which are so important to Catalonia and Spain.”

Xavier Castillejo, Mayor of Lliçà de Vall, stated that “the facility will contribute to the development of the Vallès Oriental region and create opportunities for people and future generations.”

Raimon Grifols said, “The laying of this foundation stone symbolizes Grifols’ commitment to continued growth rooted in the region, with an industrial vision focused on serving patients. This new plant will enable us to expand our production capacity for plasma-derived medicines in Europe and contribute to strengthening the continent’s strategic autonomy and self-sufficiency. From Vallès Oriental, where we have carried out industrial activity for more than five decades, we continue to build the future with a commitment to ensuring that more patients can access essential therapies.”

The plant represents an initial investment of EUR 160 million. Once completed, it will increase Grifols’ plasma fractionation capacity in Europe by three million liters, further strengthening the company’s ability to ensure the supply of essential medicines, such as immunoglobulins and other plasma-derived treatments, for the more than 300,000 patients across the continent.

The new facilities in Lliçà de Vall will join Grifols’ complex in Parets del Vallès (Barcelona) to form a 25-hectare biotechnology hub with more than 3,700 employees, including 400 newly created jobs.

The center will include a plasma fractionation plant, logistics operations, a testing laboratory and warehouses. It will also feature a new space for Grifols Engineering, which - recognized globally for designing world-class biopharmaceutical facilities - will design and construct the Lliçà de Vall expansion.

A strategic project based on a highly digitalized, sustainable smart factory model

The Lliçà de Vall expansion has been designated a strategic project by the Government of Catalonia. Conceived as a next-generation facility based on a smart factory model, it will leverage digitalization and advanced data systems to optimize production, enhance operational efficiency, reduce energy and water consumption and minimize waste compared to conventional facilities.

As a global leader in environmental sustainability, Grifols integrates energy efficiency, digitalization and circular-economy principles into the design of its industrial facilities with the aim of minimizing its environmental impact and advancing toward a responsible, long-term growth model.

The company expects the new plant to operate using 100% renewable electricity and is exploring the integration of a biogas facility capable of supplying up to 30% of its natural gas needs. This builds on the experience of the Parets del Vallès complex, where Grifols operates an anaerobic treatment plant that has reduced organic pollutant load by 85% and generates renewable biogas used as fuel in the production process.

The campus will also incorporate intelligent resource-monitoring and management systems to optimize energy and water use. Through these measures, Grifols aims to improve energy efficiency by 15%, reduce emissions by 60% and achieve approximately 20% water savings - reinforcing its commitment to a responsible energy transition that exceeds regulatory requirements.

The project integrates circular-economy best practices, enabling the reuse, recycling, repair and repurposing of materials throughout their life cycles. The planned biogas facility would further support this approach by generating renewable energy from industrial by-products.

The investment in Lliçà de Vall reflects Grifols’ longstanding commitment to generating economic and social value in the regions where it operates. In Spain, Grifols currently employs more than 4,700 people and supports over 16,000 indirect jobs - contributing an estimated more than EUR 1.5 billion to the national economy.